Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you sir! i appreciate that.
Good luck, zarathos with your future investments, i am not selling now!
Yup, very well said.
Learnt , two thing, in trading, dont do panic buying and panic selling.
I am not selling either. There was nothing new in 10 K except language was too harsh. We know there is no partnership or financing done and we know they are running low in cash. I dont understand what chaged it so much !
Will wait for the CC.
(Reuters) - AVI BioPharma Inc's shares could get a boost if its drug targeting treatment for a rare fatal form of muscular dystrophy proves to be effective in clinical drug trials, according to an article in the April 2 edition of Barron's.
Clinical trial results for AVI's drug Eteplirsen were expected later this month, Barron's said. The drug is designed to treat Duchenne muscular dystrophy, a disease that develops in early childhood and most often results in the death by age 30. The disease strikes only boys, about one in 3,500, and affects more than 30,000 people in the United States, Europe and Japan.
Favorable results could boost AVI's shares, which have doubled this year, Barron's said. Its shares closed at $1.54 on the Nasdaq on Friday.
ThinkEquity analyst Marko Kozul has targeted AVI shares at $4, Barron's said.
AVI also was developing drugs for Ebola and Marburg viruses with U.S. Department of Defense funding, Barron's said.
(Reporting By Ilaina Jonas; Editing by Maureen Bavdek)
HEALTHHOT STOCKSASIAN MARKETS
Related Quotes and News
COMPANYPRICERELATED NEWS
AVI BioPharma Inc
AVII.O
$1.54
+0.03+1.99%
AVII : DMD is the most common genetic muscular dystrophy . Let's all hope this drug is successful , not just for profit but also for those children , if the drug is successful it will change the lives of those kids enormously.
AVII:
BOTHELL, WA, Mar 30, 2012 (MARKETWIRE via COMTEX) -- AVI BioPharma, Inc. AVII +1.99% , a developer of RNA-based therapeutics, today announced it will hold a conference call at 8:00 a.m. EDT (5:00 a.m. PDT) on Monday, April 2, 2012 to discuss top-line results from its Phase IIb study evaluating eteplirsen for the treatment of Duchenne Muscular Dystrophy (DMD).
The conference call may be accessed by dialing 800.561.2718 for domestic callers and 617.614.3525 for international callers. The passcode for the call is 99858553. Please specify to the operator that you would like to join the "AVI BioPharma Phase IIb Top-Line Data Results Call." The conference call will be webcast live under the events section of AVI's website at www.avibio.com and will be archived there following the call for 90 days. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Avii , to announce phase IIb data with Cc at 8 am Est Monday morning. Good luck to all longs . Holding 15 K shares. Should be positive data. Sheff has given excellent DD.
Yes agree , pernonck is F ash****.
Where did you get this info, i went to company website and sec. and find nothing. Thanks.
Chtp halted
Still holding my mapp shorts at 16.03, unbelievable action, it tocuhed 52 week high today. Pure manipulation by MM. will hold my shorts for now.
MAPP: I really think the way company has tried to deceive investors, they are facing class action lawsuit, just my opinion , we shall see.
MAPP: I think it's CRL , just because they are taking so long for PR , more than one hour since it was halted and fda SPOX said, " ask the company about it". Lets, see what happens, keeping my finger crossed. This is just my speculation and i may be wrong.
OT: iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB)at all time high of 123 $.
Watching MAPP closely here for possible CRL
MAPP: Thank you so much Sheff. I am short 1000 shares @ 16.03
MAPP: sheff what is your opinion. Its, a inhaler for migraine for which fairly good therapies exist. I dont think FDA whould approve a inhaled migraine medication at the first go. TA
Great job sheff, i was not in it, congrates to those who profited from it!
$GTXI, Citi's top biotech pick for 2012, $19 target
Great point wind. Here is some quote from dew's post and my comments,
Louis P. Scafuri, Chief Executive Officer of Syneron Medical, said, "Juvenis has developed a very unique dermal filler technology that provides advantages over the currently approved products and represents an attractive, multi-billion-dollar new commercial opportunity for Syneron.
We expect that Tenergel will be ideal for high-volume aesthetic applications and body contouring procedures given its tissue-like feel and its slow and natural degradation in the body. In addition, Tenergel is expected to have significant cost advantages over currently approved products and has strong intellectual property protection. We also believe that it can be an excellent product for wrinkles and lip augmentation procedures, further expanding its market opportunity."
CORT: should be announcing financing soon @3- 3.50, still holding my shorts @ avg of around 3.40.
YMI- Sold all of my YMI @ AVG. 1.97 from my entry of 1.64 AVG, did not liked the dilution at all at this stage , no ASCO presentation announcement, No partnership talks. Still a good long term hold, will re-enter in the future. $YMI
TLON, breifing docs don,t look good to me. Of course my assessment can be wrong as i have been wrong in the past, $TLON.
OT: NIH budget petition .
Guys today is the last day to sign this petition , many jobs in the research depend on our signatures , follow the link below and sign it please , today is the last day ,
http://wh.gov/81O
Been on a long vacation, will post more. Great post sheff really motivates small traders like me.
Still long, holding 15 K shares.
Many people dont even try!
You are doing a great job! keep it up. $YMI
23 cents from your target, LOL
Well done kipper
good poster name buddy, i just learned my lesson with CORT.
You won't find $600 subscription fees to get good info here. If you or anyone else is paying a subscription service for biotech information I will personally smack you between the eyes:)
CONGRATES , VERY NICE CALL
Lesson learned, good call from you. GOOD luck, you were right i was wrong